Mandate

Vinge advises Industrifonden in connection with its investment in solar cells company, Sol Voltaics

July 04, 2011

Vinge has advised Stiftelsen Industrifonden in connection with its SEK 18.5 million investment in the solar cells company, Sol Voltaics. Sol Voltaics has developed a completely new type of material which can significant reduce the cost of producing electricity from solar cells. The total amount of the issue is SEK 40 million and the capital will be used for the future development of the company’s products. Sol Voltaics has developed a new material and a new production method for the manufacture of solar cells. In brief, it is based upon the rapid production of nano threads of gallium arsenide (GaAs), where each thread is a solar cell. This material has been widely recoginsed for some time as the best way of manufacturing solar cells although up to now it has been too expensive to use. Sol Volatics has now developed a method which can radically reduce the costs associated with the aforementioned method.

Vinge’s team consisted of Johan Larsson (project manager) and Claes Henriksson. Johan Winnerblad was the responsible partner.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025